Results 191 to 200 of about 20,698 (251)

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source

Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis. [PDF]

Endocrinol Diabetes Metab
Kow CS, Thiruchelvam K, Ramachandram DS, Zaihan AF.   +3 more
europepmc   +1 more source

Effects of GLP‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review

The FEBS Journal, EarlyView.
This systematic review evaluated 17 studies (12 preclinical and five clinical) on GLP‐1 receptor agonists in type 2 diabetes, demonstrating effects on the gut microbiota and metabolic improvement. The studies showed an increase in Bacteroidetes, Lactobacillus, and Akkermansia, and a reduction in Firmicutes.
Ranicleide Santos Dantas, Lucas Vinícius Souza Santos, André Gustavo Carvalho de Oliveira, Marina dos Santos Barreto, Deise Maria Rego Rodrigues Silva, Pedro Henrique Macedo Moura, Eloia Emanuelly Dias Silva, Ronaldy Santana Santos, Lucas Alves da Mota Santana, Rajiv Gandhi Gopalsamy, Adriana Gibara Guimarães, Lysandro Pinto Borges   +11 more
wiley   +1 more source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss. [PDF]

NPJ Metab Health Dis
Murugadoss K, Venkatakrishnan AJ, Soundararajan V.   +2 more
europepmc   +1 more source

Role of glucagon in metabolic diseases

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes.
Tadahiro Kitamura, Yoko Tabei, Masaki Kobayashi   +2 more
wiley   +1 more source

Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study​. [PDF]

Cureus
Raj FP, Boo H, Kenney A, Espiridion E.
europepmc   +1 more source

Association of GLP‐1 Receptor Agonists With Gastrointestinal and Liver Outcomes in Adults With Type 2 Diabetes: A Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Dazheng Zhang, Ying Lu, Xinyao Jian, Haoyuan Wang, Jacquelyn Hatch‐Stein, Ronen Stein, Jennifer Panganiban, Yong Chen   +7 more
wiley   +1 more source

Use of glucagon‐like peptide‐1 receptor agonists is associated with inadequate bowel preparation for colonoscopy in patients with diabetes

Journal of Diabetes Investigation, EarlyView.
In Japanese patients with diabetes undergoing colonoscopy, GLP‐1RA use was associated with a higher rate of inadequate bowel preparation after propensity score matching. Weekly formulations showed a higher rate than daily formulations, while additional adjusted analyses were directionally consistent but not statistically significant.
Osamu Ogawa
wiley   +1 more source

Tirzepatide non-response with subsequent semaglutide response in class 2 obesity. [PDF]

JCEM Case Rep
La Vignera S, Condorelli RA.
europepmc   +1 more source